

DAFTAR PUSTAKA

- [1] World Health Organization. WHO coronavirus disease (COVID-19) dashboard. WHO [https://covid19.who.int/\(2020\)](https://covid19.who.int/(2020)).
- [2] Worldometer. (2020) Corona virus update. Available at : https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1?%22(accessed 15 November 2020)
- [3] Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *J Adv Res.* 2020;24(April):91–8.
- [4] Wasito, Hartari W. (2020). *Corona Virus (Sars, Mers, Covid-19)*. Lily Publisher: Yogyakarta.
- [5] Enjuanes L et al. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. *Virus Res.* 2008;133(1):45-62
- [6] D.Calina, D.Oana. Towards effective COVID - 19 vaccines : Updates , perspectives and challenges (Review).2020. DOI: 10.3892/ijmm.2020.4596
- [7] BBC (2020) Coronavirus: human trial of new vaccine begins in UK, 24 June 2020. Available at: <https://www.bbc.com/news/health-53061288> (accessed 26 June 2020).
- [8] Morse, J. S., Lalonde, T., Xu, S., & Liu, W. (2020). Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019nCoV. *Chemistry and Biochemistry* 21(5), 730-738.
- [9] Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., Neuman, B. W., et al. (2020). The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nature Microbiology* 5, 536-544
- [10] Zhou P et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature.* 2020;579:270-3.
- [11] Decaro N, Lorusso A. Novel human coronavirus (SARS-CoV-2): A lesson from animal coronaviruses. *Vet Microbiol.* 2020;244(March):108693.
- [12] Huang B, Ling R, Cheng Y, Wen J, Dai Y, Huang W, et al. Characteristics of the

Coronavirus Disease 2019 and related Therapeutic Options. *Mol Ther - Methods Clin Dev.* 2020;18(September):367–75.

- [13] Huang B, Ling R, Cheng Y, Wen J, Dai Y, Huang W, et al. Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options. *Mol Ther - Methods Clin Dev.* 2020;18(September):367–75
- [14] Zhang L, Guo H. Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. *Adv Biomark Sci Technol.* 2020;2:1–23.
- [15] Amirfakhryan H, Safari F. Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement. *Hell J Cardiol.* 2020;
- [16] Swerdlow DL, Finelli L. Preparation for Possible Sustained Transmission of 2019 Novel Coronavirus: Lessons From A Previous Epidemics. *Jama.* 2020; 323(12):1129–30
- [17] WHO. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. 2020
- [18] Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zou W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. 2020; 1-13
- [19] Wu P, Hao X, Lau EH, Wong JY, Leung KSM, Wu JT, dkk. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. *Rapid Communication.* 2020; 25(3):1-6
- [20] Cai H. Sex difference and smoking predisposition in patients with COVID-19. *Lancet Respir Med.* 2020; published online March 11. DOI: 10.1016/S2213-2600(20)30117-X
- [21] Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir Med.* 2020; published online March 11. DOI: 10.1016/S2213-2600(20)30116-8.
- [22] European Society of Cardiology. Position Statement of the ESC Council on Hypertension on ACEInhibitors and Angiotensin Receptor Blockers [Internet]. 2020 [updated 2020 March 13; cited 2020 March 22]. Available from: [https://www.escardio.org/Councils/Council-on-Hypertension-\(CHT\)/News/positionstatement-of-the-esc-council-on-hypertension-on-ace-inhibitorsand-ang](https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/positionstatement-of-the-esc-council-on-hypertension-on-ace-inhibitorsand-ang).
- [23] Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol.* 2020; published online March 4. DOI: 10.1016/S2468-1253(20)30057-1.
- [24] Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for cancer patients.

Lancet Oncol. 2020; published online March 3. DOI: 10.1016/S1470-2045(20)30150-9.

[25] Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020; published online March 20. DOI: 10.1016/S2468-1253(20)30084-4.

[26] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New Engl J Med. 2020; published online February 28. DOI: 10.1056/NEJMoa2002032.

[27] Amirfakhryan H, Safari F. Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement. Hell J Cardiol. 2020;

[28] Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81:e16–25.

[29] Prevention CfDCa. Interim US Guidance for Risk Assessment and Public Health Management of Persons with Potential Coronavirus Disease 2019 (COVID-19) Exposures: Geographic 65Jurnal Penyakit Dalam Indonesia | Vol. 7, No. 1 | Maret 2020 |Risk and Contacts of Laboratory-confirmed Cases [Internet]. 2020 [updated 2020 March 7; cited 2020 March 20]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/php/riskassessment.html>.

[30] International Council of Nurses. High proportion of healthcare workers with COVID-19 in Italy is a stark warning to the world: protecting nurses and their colleagues must be the number one priority. Geneva: International Council of Nurses; 2020.

[31] Wang J, Zhou M, Liu F. Exploring the reasons for healthcare workers infected with novel coronavirus disease 2019 (COVID-19) in China. J Hosp Infect. 2020; published online March 5. DOI: 10.1016/j.jhin.2020.03.002.

[32] Arifianto.2020.Yakin Dengan Vaksin dan Imunisasi.Kata Depan: Jakarta

[33] Chitra Nagarajan. “In Search of a COVID-19 Vaccine.” IOSR Journal of Dental and Medical Sciences (IOSR-JDMS), 19(5), 2020, pp. 22-29.

[34] Sridhar S, Brokstad KA and Cox RJ: Influenza vaccination strategies: Comparing inactivated and live attenuated influenza vaccines. Vaccines (Basel) 3: 373- 389, 2015

[35] Food and Drug Administration. Vaccines Lisenced for Use in the United State [Internet]. [cited 2020 May 27]. Available from: <https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/>

- [36] Herrera-Rodriguez J, Signorazzi A, Holtrop M, de Vries-Idema J, Huckriede A. Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production. *Vaccine*. 2019;37(12):1630–7. <https://doi.org/10.1016/j.vaccine.2019.01.086>
- [37] Halstead SB, Thomas SJ. New Japanese encephalitis vaccines: Alternatives to production in mouse brain. *Expert Rev Vaccines*. 2011;10(3):355–64. <https://doi.org/10.1586/erv.11.7>
- [38] Jarmer J, Zlatkovic J, Tsouchnikas G, Vratskikh O, Strauss J, Aberle JH, et al. Variation of the Specificity of the Human Antibody Responses after Tick-Borne Encephalitis Virus Infection and Vaccination. *J Virol*. 2014;88(23):13845–57. <https://doi.org/10.1128/jvi.02086-14>
- [39] Tseng C Te, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. *PLoS One*. 2012;7(4). <https://doi.org/10.1371/journal.pone.0035421>
- [40] Lauring AS, Jones JO and Andino R: Rationalizing the development of live attenuated virus vaccines. *Nat Biotechnol* 28: 573- 579, 2010.
- [41] Polio Global Eradication Initiative. Oral Polio Vaccine [Internet]. [cited 2020 May 26]. Available from: <http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/opv-cessation/>
- [42] Hawksworth A, Jayachander M, Hester S, Mohammed S, Hutchinson E. Proteomics as a tool for live attenuated influenza vaccine characterisation. *Vaccine*. 2020;38(4):868–77. <https://doi.org/10.1016/j.vaccine.2019.10.082>
- [43] Netland J, DeDiego ML, Zhao J, Fett C, Álvarez E, Nieto-Torres JL, et al. Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. *Virology*. 2010;399(1):120–8. <https://doi.org/10.1016/j.virol.2010.01.004>
- [44] Calina Daniela .2020. Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review). *International Journal Of Molecular Medicine*. DOI: 10.3892/ijmm.2020.4596
- [45] Zhang N, Tang J, Lu L, Jiang S and Du L: Receptor-binding domain-based subunit vaccines against MERS-CoV. *Virus Res* 202: 151- 159, 2015.
- [46] Lee NH, Lee JA, Park SY, Song CS, Choi IS and Lee JB: A review of vaccine development and research for industry animals in Korea. *Clin Exp Vaccine Res* 1: 18- 34, 2012.
- [47] Wang M, Jiang S and Wang Y: Recent advances in the production of recombinant

subunit vaccines in *Pichia pastoris*. *Bioengineered* 7: 155- 165, 2016.

- [48] Liu C, Zhou Q, Li Y, Garner L V., Watkins SP, Carter LJ, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. *ACS Cent Sci.* 2020;6(3):315–31. <https://doi.org/10.1021/acscentsci.0c00272>
- [49] Thanh LeT, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. *Nat Rev Drug Discov.* 2020;19(5):305–6. <https://doi.org/10.1038/d41573-020-00073-5>
- [50] Gilbert SC, Warimwe GM. Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology. *Vaccine.* 2017;35(35):4461–4. <https://doi.org/10.1016/j.vaccine.2017.04.085>
- [51] Choi Y and Chang J: Viral vectors for vaccine applications. *Clin Exp Vaccine Res* 2: 97- 105, 2013.
- [52] Grenham A and Villafana T: Vaccine development and trials in low and lower- middle income countries: Key issues, advances and future opportunities. *Hum Vaccin Immunother* 13: 2192- 2199, 2017.
- [53] Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, Buchholz UJ, Openshaw PJ, McLellan JS, Englund JA, et al; Respiratory Syncytial Virus Network (ReSViNET) Foundation: The respiratory syncytial virus vaccine landscape: Lessons from the graveyard and promising candidates. *Lancet Infect Dis* 18: e295- e311, 2018.
- [54] Schlake T, Thess A, Fotin-Mleczek M and Kallen KJ: Developing mRNA- vaccine technologies. *RNA Biol* 9: 1319- 1330, 2012.
- [55] Jackson NAC, Kester KE, Casimiro D, Gurunathan S and DeRosa F: The promise of mRNA vaccines: A biotech and industrial perspective. *NPJ Vaccines* 5: 11, 2020.
- [56] Zhang C, Maruggi G, Shan H and Li J: Advances in mRNA Vaccines for infectious diseases. *Front Immunol* 10: 594, 2019.
- [57] Hasson SSAA, Al-Busaidi JKZ, Sallam TA. The past, current and future trends in DNA vaccine immunisations. *Asian Pac J Trop Biomed.* 2015;5(5):344–53. [https://doi.org/10.1016/S2221-1691\(15\)30366-X](https://doi.org/10.1016/S2221-1691(15)30366-X)
- [58] Ulmer JB, Mason PW, Geall A, Mandl CW. RNA-based vaccines. *Vaccine.* 2012;30(30):4414–8. <https://doi.org/10.1016/j.vaccine.2012.04.060>
- [59] Li L and Petrovsky N: Molecular mechanisms for enhanced DNA vaccine immunogenicity. *Expert Rev Vaccines* 15: 313- 329, 2016

- [60] Tsatsakis A, Petrakis D, Nikolouzakis TK, Docea AO, Calina D, Vinceti M, Goumenou M, Kostoff RN, Mamoulakis C, Aschner M, et al: COVID- 19, an opportunity to reevaluate the correlation between long- term effects of anthropogenic pollutants o
- [61] Han S: Clinical vaccine development. Clin Exp Vaccine Res 4: 46- 53, 2015.
- [62] Kamal AM, Mitrut P, Docea AO, Soşoi S, Kamal KC, Mitrut R, Mărgăritescu D, Călina D, Banciu C, Tica OS, et al: Double therapy with pegylated Interferon and Ribavirin for chronic hepatitis C. A pharmacogenetic guide for predicting adverse events. Farmacia 65: 877- 884, 2017.
- [63] Black S: The costs and effectiveness of large Phase III pre- licensure vaccine clinical trials. Expert Rev Vaccines 14: 1543- 1548, 2015.
- [64] NIH clinical trial of investigational vaccine for COVID-19 begins. US National Institutes of Health. (16 Mar 2020). Accessed 30 April 2020
- [65] Wang, F., Richard M. K., dan George B. S. (2020). An Evidence Based Perspective on mRNASARS-CoV-2 Vaccine Development. Medical Science Monitor, 26, 1-8. <https://doi.org/10.12659/MSM.924700>
- [66] Jeff Craven. Covid-19 Vaccine tracker. Updated May 7, 2020. <https://www.raps.org/news-and-articles/news-articles/2020/3/covid19-vaccine-tracker>. Accessed 15 May 2020
- [67] Zhu, F.-C., Yu-Hua L., Xu-Hua G., Li-Hua H., Wen-Juan W., Jing-Xin L., dan Wei C. (2020). Safety, Tolerability, and Immunogenicity of Recombinant Adenovirus Type-5 Vektored COVID-19 Vaccine: A Dose-escalation, Open-label, Non-randomised, First-in-human Trial. Elsevier Ltd, 1-10. [https://doi.org/10.1016/S0140-6736\(20\)31208-3](https://doi.org/10.1016/S0140-6736(20)31208-3)
- [68] John Xie. China announces phase 2 of clinical trial of COVID-19 vaccine. (15 Apr 2020) <https://www.voanews.com/covid-19pandemic/china-announces-phase-2-clinical-trials-covid-19-vaccine>.
- [69] Qiang Gao, Linlin Bao , Haiyan Mao , Lin wang et al., Development of an inactivated vaccine candidate for SARS-CoV-2. Science (06 May 2020). DOI: 10.1126/science.abc1932
- [70] Gao, Q., Linlin B., Haiyan M., Lin W., Kangwei X., Minnan Y., Yajing L., dan Chun Q. (2020). Rapid Development of an Inactivated Vaccine Candidate for SARS-CoV-2. Science, 1-10. <https://doi.org/10.1126/science.abc1932>
- [71] World Health Organization. WHO vaccine administration route dashboard.

<https://in.vaccine-safety-training.org/route-of-administration.html>

- [72] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 2020;1–3.
- [73] Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. *MBio* 2018;9 (2):e00221–e318.
- [74] Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. *bioRxiv*; 2020.
- [75] Bisht H, Roberts A, Vogel L, Subbarao K, Moss B. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. *Virology* 2005;334(2):160–5
- [76] Zheng BJ, Guan Y, Wong KH, Zhou J, Wong KL, Young BWY, et al. SARS-related virus predating SARS outbreak, Hong Kong. *Emerg Infect Dis* 2004;10(2):176.
- [77] Kam YW, Kien F, Roberts A, Cheung YC, Lamirande EW, Vogel L, et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγR2-dependent entry into B cells in vitro. *Vaccine* 2007;25(4):729–40.
- [78] Kapadia SU, Rose JK, Lamirande E, Vogel L, Subbarao K, Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. *Virology* 2005;340 (2):174–82.
- [79] Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. *Proc Natl Acad Sci* 2004;101(17):6641–6.
- [80] Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. *Proc Natl Acad Sci* 2004;101 (26):9804–9.
- [81] Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, et al. Mucosal immunisation of African green monkeys (*Cercopithecus aethiops*) with an attenuated parainfluenza virus

expressing the SARS coronavirus spike protein for the prevention of SARS. *Lancet* 2004;363 (9427):2122–7.

- [82] See RH, Zakhartchouk AN, Petric M, Lawrence DJ, Mok CP, Hogan RJ, et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. *J Gen Virol* 2006;87(3):641–50.
- [83] Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. *J Virol* 2004;78(22):12672–6.
- [84] Spruth M, Kistner O, Savidis-Dacho H, Hitter E, Crowe B, Gerencer M, et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. *Vaccine*. 2006;24(5):652–61.
- [85] Tang L, Zhu Q, Qin E, Yu M, Ding Z, Shi H, et al. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. *DNA Cell Biol* 2004;23(6):391–4.
- [86] Qin E, Shi H, Tang L, Wang C, Chang G, Ding Z, et al. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. *Vaccine* 2006;24(7):1028–34.
- [87] Zhou J, Wang W, Zhong Q, Hou W, Yang Z, Xiao S-Y, et al. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. *Vaccine* 2005;23(24):3202–9
- [88] Qu D, Zheng B, Yao X, Guan Y, Yuan Z-H, Zhong N-S, et al. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. *Vaccine* 2005;23(7):924–31.
- [89] Saif LJ. Vaccines for COVID-19: Perspectives, Prospects, and Challenges Based on Candidate SARS, MERS, and Animal Coronavirus Vaccines. 2020;(March).
- [90] Xu, Jianqing. SARS-CoV-2: an unknown agent and challenges in vaccine development. *Bio-X*(2020) 3:3-5
- [91] Jeyanathan, Mangalakumari. Immunological considerations for COVID-19 vaccine strategies. *Nature reviews* 21 May 2020
- [92] Tambornino L, Lanzerath D. COVID-19 human challenge trials – what research

ethics committees need to consider. 2020; 4

- [93] J, Wang Y, Peng, H, Xu et al. The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. *AAPS PharmSciTech*. (2020) 21:225 DOI: 10.1208/s12249-020-01744-7
- [94] Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D., & Fouchier, R. A. (2012). Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *New England Journal of Medicine* 367(19), 1814-1820.
- [95] Baez-Santos, Y. M., St. John, S. E., & Mesecar, A. D. (2015). The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. *Antiviral Research*, 115, 21-38
- [96] Chowell, G., Abdirizak, F., Lee, S., Lee, J., Jung, E., Nishiura, H., & Viboud, C. (2015). Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. *BMC Medicine* 13, 210.
- [97] Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., Hui, D. S., et al. (2020). Clinical characteristics of 2019 novel coronavirus infection in China. *New England Journal of Medicine* 382, 1708-1720.
- [98] Rothe, C., Schunk, M., Sothmann, P., Bretzel, G., Froeschl, G., Wallrauch, C., Zimmer, T., Thiel, V., Janke, C., Guggemos, W., et al. (2020). Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. *New England Journal of Medicine* 382, 970-971
- [99] Bai. Y., Yao, L., Wei, T., Tian, F., Jin, D. Y., Chen, L., & Wang, M. (2020). Presumed Asymptomatic Carrier Transmission of COVID-19. *Journal of American Medical Association*. <https://doi.org/10.1001/jama.2020.2565>.
- [100] Holmes EC, Zhang Y-Z. Novel 2019 coronavirus genome [Internet]. *virological.org*. 2020 [cited 2020 May 26]. Available from: <http://virological.org/t/novel-2019-coronavirus-genome/319>
- [101] Garden R. Remarks by President Trump on vaccine development [Internet]. 2020 [cited 2020 May 25]. Available from: <https://www.whitehouse.gov/briefings-statements/remarks-president-trump-vaccine-development/>
- [102] Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *bioRxiv*. 2020.
- [103] Roper RL, Rehm KE. SARS vaccines: where are we? *Expert Rev Vaccines*. 2009;8(7):887-98.

- [104] Enjuanes L et al. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. *Virus Res.* 2008;133(1):45-62.
- [105] Schindewolf C, Menachery VD. Middle east respiratory syndrome vaccine candidates: cautious optimism. *Viruses.* 2019;11(1). pii: E74
- [106] Vandamme TF: Use of rodents as models of human diseases. *J Pharm Bioallied Sci* 6: 2-9, 2014
- [107] Vergara-Alert J et al. Livestock susceptibility to infection with middle east respiratory syndrome coronavirus. *Emerg Infect Dis.* 2017;23(2):232-40.
- [108] Chen W et al. 2005. SARS-associated coronavirus transmitted from human to pig. *Emerg Infect Dis* 2005;11:446- 448.
- [109] Vlasova A N et al, "Gnotobiotic neonatal pig model of rotavirus infection and disease," Svensson L et al. (eds), *Viral gastroenteritis: molecular epidemiology and pathogenesis* (2016). The Netherlands: Elsevier, pp. 219-41.
- [110] Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020. doi:10.1038/s41586-020-2012-7.
- [111] Buchholz, U. J. et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. *Proc. Natl Acad.Sci.* 101, 9804–9809 (2004).
- [112] Ahmed, S. F., Quadeer, A. A. & McKay, M. R. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS- CoV-2) based on SARS- CoV immunological studies. *Viruses* 12, 254 (2020).
- [113] Stephensen, C. B., Casebolt, D. B. Gangopadhyay, N. N. Phylogenetic analysis of a highly conserved region of the polymerase gene from 11 coronaviruses and development of a consensus polymerase chain reaction assay. *Virus Res.* 60, 181–189 (1999).
- [114] Gao, Y. et al. Structure of the RNA- dependent RNA polymerase from COVID-19 virus. *Science* 368, 779–782 (2020). Lurie, Nichole at all. Developing Covid-19 Vaccines at Pandemic Speed. *n engl j med* 382;21(2020)
- [115] Lurie, Nichole at all. Developing Covid-19 Vaccines at Pandemic Speed. *n engl j med* 382;21(2020)
- [116] Jamrozik E and Selgelid MJ (2020) COVID-19 human challenge studies: ethical issues. *The Lancet Infectious Diseases*. Epub ahead of print 29 May 2020. DOI: 10.1016/.

- [117] Metzger WG, Ehni HJ, Kremsner PG, et al. (2019) Experimental infections in humans — historical and ethical reflections. *Tropical Medicine and International Health* 24(12): 1384–1390. DOI: 10.1111/tmi.13320.
- [118] NHS (2020) COVID-19 hospital discharge service requirements. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/880288/COVID-19_hospital_discharge_service_requirements.pdf (accessed 26 June 2020).
- [119] Eyal N, Lipsitch M and Smith PG (2020) Human challenge studies to accelerate coronavirus vaccine licensure. *The Journal of Infectious Diseases* 221(11): 1752–1756. DOI: 10.1093/infdis/jiaa152.
- [120] Chappell RY and Singer P (2020) Pandemic ethics: the case for risky research. *Research Ethics*. Epub ahead of print 2 June 2020. DOI: 10.1177/2F1747016120931920.
- [121] ICH Topic E 8 (1998) General considerations for clinical trials. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-8-general-considerations-clinicaltrials-step-5_en.pdf (accessed 16 June 2020).
- [122] Council for International Organizations of Medical Sciences (CIOMS) (2016) International ethical guidelines for health-related research involving humans. 4th edn. Available at <https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf> (accessed 16 June 2020).
- [123] Tomar J, Tonnis WF, Patil HP, de boer AH, Hagedoorn P, Vanbever R, et al. Pulmonary immunization: deposition site is of minor relevance for influenza vaccination but deep lung deposition is crucial for hepatitis B vaccination. *Acta Pharm Sin B* [Internet]. 2019;9(6):1231–40. Available from: <https://doi.org/10.1016/j.apsb.2019.05.003>.
- [124] Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S, et al. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS. *J Immunol* [Internet]. 2008;180(2):948–56. Available from: <https://doi.org/10.4049/jimmunol.180.2.948>.
- [125] Matthias DM, Robertson J, Garrison MM, Newland S, Nelson C. Freezing temperatures in the vaccine cold chain: a systematic literature review. *Vaccine* [Internet]. 2007;25(20):3980–6. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0264410X07002289>.
- [126] Niu L, Panyam J. Freeze concentration-induced PLGA and polystyrene nanoparticle aggregation: Imaging and rational design of lyoprotection. *J Control*

Release [Internet]. 2017;248:125–132. Available from: <https://doi.org/10.1016/j.jconrel.2017.01.019>

- [127] Temperature sensitivity of vaccines [Internet]. World Health Organization; 2006. Available from: <https://apps.who.int/iris/handle/10665/69387>
- [128] Zolgensma, Package insert. Bannockburn: AveXis, Inc.;2019.
- [129] Pastorino B, Baronti C, Gould EA, Charrel RN, de Lamballerie X. Effect of Chemical Stabilizers on the Thermostability and Infectivity of a Representative Panel of Freeze Dried Viruses. Digard P, editor. PLoS One [Internet]. 2015;10(4):e0118963. Available from: <https://doi.org/10.1371/journal.pone.0118963>.
- [130] Aso Y, Yoshioka S. Effect of freezing rate on physical stability of lyophilized cationic liposomes. Chem Pharm Bull (Tokyo) [Internet]. 2005;53(3):301–4 Available from: <http://joi.jlc.jst.go.jp/JST.JSTAGE/cpb/53.301?from=CrossRef>.
- [131] Li X, Thakkar SG, Ruwona TB, Williams RO, Cui Z. A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution. J Control Release [Internet]. 2015;204:38–50. Available from: <https://doi.org/10.1016/j.jconrel.2015.02.035>.
- [132] Ordovas- Montanes, J., Beyaz, S., Rakoff- Nahoum, S.& Shalek, A. K. Distribution and storage of inflammatory memory in barrier tissues. *Nat. Rev. Immunol.* 20, 308–320 (2020).
- [133] Cardani, A., Boulton, A., Kim, T. S. & Braciale, T. J. Alveolar macrophages prevent lethal influenza pneumonia by inhibiting infection of type-1 alveolar epithelial cells. *PLoS Pathog.* 13, e1006140 (2017).
- [134] Guillon, A. et al. Pneumonia recovery reprograms the alveolar macrophage pool. *JCI Insight* 5, e133042 (2020).
- [135] Yao, Y. et al. Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity. *Cell* 175, 1634–1650.e17 (2018).
- [136] Xing et al. (2020), Netea et al. (2020) and Yao et al. describe the emerging concept of trained innate immunity and suggest strategies to harness this concept for developing vaccines against respiratory mucosal pathogens such as SARS-CoV-2.
- [137] Rudraraju R et al. How live attenuated vaccines can inform the development of broadly cross-protective influenza vaccines. *J Infect Dis.* 2019;219 (Supplement1):S81-7.

- [138] Lu LL, Suscovich TJ, Fortune SM, et al. Beyond binding: antibody effector functions in infectious diseases. *Nat Rev Immunol* 2018;18: 46–61.
- [139] Zhou Y, Fu B, Zheng X, et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. *bioRxiv* 2020. <https://www.biorxiv.org/content/10.1101/2020.02.12.945576v1>.
- [140] Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for 2019-nCoV based on SARS-CoV immunological studies. *bioRxiv* 2020; <https://www.biorxiv.org/content/10.1101/2020.02.03.933226v4.full>.
- [141] Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. *medRxiv* 2020. <https://www.medrxiv.org/content/10.1101/2020.02.16.20023671v1.full.pdf+html>.
- [142] Diao B. Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19). *medRxiv* 2020. <https://www.medrxiv.org/content/10.1101/2020.02.18.20024364v1.full.pdf>.
- [143] Wouters-Wesseling W, Rozendaal M, Snijder M, Graus Y, Rimmelzwaan G, De Groot L and Bindels J: Effect of a complete nutritional supplement on antibody response to influenza vaccine in elderly people. *J Gerontol A Biol Sci Med Sci* 57: M563-M566, 2002.
- [144] Tsoukalas D, Fragkiadaki P, Docea AO, Alegakis AK, Sarandi E, Vakonaki E, Salataj E, Kouvidi E, Nikitovic D, Kovatsi L, *et al*: Association of nutraceutical supplements with longer telomere length. *Int J Mol Med* 44: 218-226, 2019.
- [145] Ventura MT, Casciaro M, Gangemi S and Buqicchio R: Immunosenescence in aging: Between immune cells depletion and cytokines up-regulation. *Clin Mol Allergy* 15: 21, 2017.
- [146] Savy M, Edmond K, Fine PE, Hall A, Hennig BJ, Moore SE, Mulholland K, Schaible U and Prentice AM: Landscape analysis of interactions between nutrition and vaccine responses in children. *J Nutr* 139: 2154S-2218S, 2009.
- [147] Arvas A: Vaccination in patients with immunosuppression. *Turk Pediatri Ars* 49: 181-185, 2014.
- [148] Chau, N. V. V. et al. The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. *Clin. Infect. Dis.* <https://doi.org/10.1093/cid/ciaa711> (2020).

- [149] Poletti, P. et al. Probability of symptoms and critical disease after SARS- CoV-2 infection. Preprint at *arXiv* <https://arxiv.org/abs/2006.08471> (2020). Chau et al. (2020) and Poletti et al. Indicate high rates of asymptomatic individuals following SARS- CoV-2 exposure.
- [150] Long, Q.-X. et al. Clinical and immunological assessment of asymptomatic SARS- CoV-2 infections. *Nat. Med.* 26, 1200–1204 (2020). This study provides evidence that asymptomatic individuals infected with SARS- CoV-2 can shed the virus for a significantly longer time than their symptomatic counterparts and that immuneresponses, including antibody responses, in asymptomatic individuals are not only lower but also decrease faster during the convalescent phase.
- [151] Nicole Lurie, M.D., M.S.P.H., Melanie Saville, M.D., Richard Hatchett, M.D., et al.; Developing Covid-19 Vaccines at Pandemic Speed. *The New England Journal of Medicine*. (30 Mar 2020) .DOI: 10.1056/NEJMp2005630 <https://www.nejm.org/doi/full/10.1056/NEJMp2005630>
- [152] Rauch, S., Jasny, E., Schmidt, K. E. & Petsch, B. New vaccine technologies to combat outbreak situations. *Front. Immunol.* 9, 1963 (2018).
- [153] DeStefano F, Bodenstab HM and Offit PA: Principal controversies in vaccine safety in the United States. *Clin Infect Dis* 69: 726-731, 2019.
- [154] Guerra Mendoza Y, Garric E, Leach A, Lievens M, Ofori-Anyinam O, Pirçon JY, Stegmann JU, Vandoolaeghe P, Otieno L, Otieno W, et al: Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: Additional data from a phase III randomized controlled trial in sub-Saharan Africa. *Hum Vaccin Immunother* 15: 2386-2398, 2019.
- [155] Dang-Tan T, Mahmud SM, Puntoni R and Franco EL: Polio vaccines, Simian Virus 40, and human cancer: The epidemiologic evidence for a causal association. *Oncogene* 23: 6535-6540, 2004.
- [156] Baylis SA, Finsterbusch T, Bannert N, Blümel J and Mankertz A: Analysis of porcine circovirus type 1 detected in Rotarix vaccine. *Vaccine* 29: 690-697, 2011.
- [157] Tetro JA: Is COVID-19 receiving ADE from other coronaviruses? *Microbes Infect* 22: 72-73, 2020. n viral epidemic/pandemic events and prevalence. *Food Chem Toxicol* (In Press).